Subconjunctival Nano- and Microparticles Sustain Retinal Delivery of Budesonide, a Corticosteroid Capable of Inhibiting VEGF Expression
Investigative Ophthalmology & Visual Science2003Vol. 44(3), pp. 1192–1192
Citations Over TimeTop 10% of 2003 papers
Abstract
Budesonide is capable of inhibiting VEGF expression through glucocorticoid receptor activity. Subconjunctivally administered budesonide-PLA nano- and microparticles sustain retinal drug delivery.
Related Papers
- → Low Dose Inhaled Budesonide and Formoterol in Mild Persistent Asthma(2001)682 cited
- → Reactions to other corticosteroids in patients with positive patch test reactions to budesonide(1995)23 cited
- [Medicinal activation and inhibition of function of glucocorticoid receptors as the basis for regulation of the glucocorticoid effect].(1994)
- → Giucocorticoid-Insensitive Bronchial Asthma(2008)
- Clinical Observation of Budesonide Inhalation for Treating Moderate and Severe Bronchia Asthma(2008)